Li Qing, Xie Hui, Jin Zefu, Huang Jing, Wang Shuting, Zhang Zijian
Department of Radiation Oncology, Affiliated Hospital of Xiangnan University, Chenzhou, People's Republic of China.
Key Laboratory of Medical Imaging and Artifical Intelligence of Hunan Province.
Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821997829. doi: 10.1177/1533033821997829.
LBX2 antisense RNA 1 (LBX2-AS1), a long noncoding RNA, has been identified to be closely associated with the progression of various cancers. However, the role of LBX2-AS1 in colorectal cancer (CRC) is still poorly understood. In this study, we aimed to investigate the expression and function of LBX2-AS1 in CRC.
Expression data from the Gene Expression Omnibus (GEO) and Gene Expression Profiling Interactive Analysis (GEPIA) databases and results obtained from clinical samples/patients were used to determine the correlation between LBX2-AS1 expression and pathological stages, overall survival (OS). Furthermore, knockdown of LBX2-AS1 in CRC cells using the short interfering RNA (siRNA) technique, and observed its biological functions using western blotting, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), cell counting kit-8 (CCK-8) and flow cytometry assay in the CRC cell line.
Our study demonstrated that the expression levels of LBX2-AS1 were higher in CRC cell lines than in normal colon mucosal cell lines. Bioinformatics analysis revealed that CRC patients with high LBX2-AS1 expression levels had poor OS. Furthermore, knockdown of LBX2-AS1 in CRC cells could attenuate the proliferative ability of CRC cells , which is associated with decreased expression of cyclin-dependent kinase (CDK) 3, CDK6, and CCND1 and enhanced expression of cyclin-dependent kinase inhibitor 1A.
LBX2-AS1 plays a crucial role in the tumorigenesis of CRC, providing a potential therapeutic target for CRC patients.
长链非编码RNA LBX2反义RNA 1（LBX2-AS1）已被证实与多种癌症的进展密切相关。然而，LBX2-AS1在结直肠癌（CRC）中的作用仍知之甚少。在本研究中，我们旨在探讨LBX2-AS1在CRC中的表达及功能。
利用基因表达综合数据库（GEO）和基因表达谱交互分析数据库（GEPIA）的表达数据以及临床样本/患者的结果，来确定LBX2-AS1表达与病理分期、总生存期（OS）之间的相关性。此外，使用短干扰RNA（siRNA）技术敲低CRC细胞中的LBX2-AS1，并通过蛋白质印迹法、定量逆转录-聚合酶链反应（qRT-PCR）、细胞计数试剂盒-8（CCK-8）和流式细胞术检测，观察其在CRC细胞系中的生物学功能。
我们的研究表明，LBX2-AS1在CRC细胞系中的表达水平高于正常结肠黏膜细胞系。生物信息学分析显示，LBX2-AS1表达水平高的CRC患者OS较差。此外，敲低CRC细胞中的LBX2-AS1可减弱CRC细胞的增殖能力，这与细胞周期蛋白依赖性激酶（CDK）3、CDK6和细胞周期蛋白D1（CCND1）表达降低以及细胞周期蛋白依赖性激酶抑制剂1A表达增强有关。
LBX2-AS1在CRC的肿瘤发生中起关键作用，为CRC患者提供了一个潜在的治疗靶点。
